
The fate of 157 government-approved global clinical trials
seemed uncertain on Monday as the Supreme Court ordered the Centre to
wait for its nod while the authorities re-examined the cases under the
new regulatory regime.
Making it clear that clinical trials
being conducted in India must be done for the benefit of the people
here, a bench of Justices R M Lodha and S K Singh directed the
government to put the trials through the new stringent three-tier test.
The Indian Express had reported that of the 162 approvals granted
by the Drug Controller General of India until August 31 this year, 157
trials were cleared in 2012, after a nod from just the New Drug Advisory
Committees (NDACs). They escaped the new regulatory regime — a
three-tier test involving the NDACs, technical committee and apex
committee — which was put in place following the SC's order in January.
Between January 1and August 31 this year, only five trials were cleared under the new three-tier test.
After Additional Solicitor General Sidharth Luthra admitted that
157 trials were not evaluated by the technical and apex committees, the
bench asked him to get it done, and submit the reports to the court by
December 16.
"The committees shall keep in view all the relevant aspects of
clinical trials and efficacy data, particularly in terms of assessment
of risk vs benefits to patients, innovation vis-a-vis existing
therapeutic options, and medical needs of the country," it said.
The bench said it would not pass any order on carrying out these
157 trials until it was satisfied that the safety of the subjects was
not being jeopardised, and that the trials would benefit India.
On the remaining five trials, the bench said they could be
proceeded with, but only after "proper framework is in place concerning
audio-video recording for informed consent of the subjects and
presentation of requisite documents while simultaneously adhering to the
principle of confidentiality".
No comments:
Post a Comment